-transparent.png){kind=logo}
34 polycythemic patients, in complete or partial stable remission, were studied for beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4) before, during and after treatment by an antiaggregating agent, ticlopidine, in comparison with 30 untreated patients. The cases with initial high value have an obvious drop, which is still maintained at the 2nd month after treatment, independent of variations of red cell and platelet counts. Any long-term protocol for clinical evaluation of antiaggregating therapy in myelo-proliferative diseases should be founded on evaluation of the markers of platelet function.
Related Publications
Y Najean, and
O Poirier
June 1987,
Rinsho byori. The Japanese journal of clinical pathology,
Y Najean, and
O Poirier
January 1983,
Sangre,
Y Najean, and
O Poirier
January 1993,
Fetal diagnosis and therapy,
Y Najean, and
O Poirier
September 1994,
Thrombosis and haemostasis,
Y Najean, and
O Poirier
January 1984,
The American journal of pediatric hematology/oncology,
Y Najean, and
O Poirier
January 1980,
Thrombosis research,
Y Najean, and
O Poirier
January 1981,
Thrombosis research,
Y Najean, and
O Poirier
January 2007,
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
Y Najean, and
O Poirier
December 1988,
Zhonghua xin xue guan bing za zhi,
Y Najean, and
O Poirier
January 1985,
Acta obstetricia et gynecologica Scandinavica,
